Tag: GlobeNewswire

Key Highlights

• Positive retail rental reversion of 10.0%¹ achieved for 1Q FY2027.
• Portfolio committed occupancy remained healthy at 94.4%², with a strong retail portfolio committed occupancy of 98.2%.
• Tenant sales grew 45.5% year-on-year (“YoY”) in 1Q FY2027. On a like‑for‑like basis, excluding PLQ Mall, tenant sales increased by 8.1% YoY.
• Weighted average cost of debt³ lowered to 2.50% per annum (vs. 2.75% per annum for FY2026).
• Reconfiguration of space at PLQ Mall is on track for completion by end-2026, with new tenants expected to enhance the mall’s positioning and support income growth.
• Retained Regional Sector Leader (Asia Retail Listed) status in the GRESB 2026 Assessment for the seventh consecutive year and recognised as Global Sector Leader (Retail Listed) while maintaining a 5 Star rating.

SINGAPORE, Oct. 30, 2026 (GLOBE NEWSWIRE) — Lendlease Global Commercial Trust Management Pte. Ltd. (the “Manager”), the manager of Lendlease Global Commercial REIT (“Lendlease REIT”), announces its first quarter business updates for FY2027.

Operational Performance

As of 30 September 2026, Lendlease REIT’s portfolio committed occupancy stood at a healthy 94.4%². The retail portfolio remained close to full occupancy at 98.2%, easing slightly from 98.5% in the prior quarter. This was mainly due to temporary vacancies from the ongoing space reconfiguration works at PLQ Mall.

The portfolio’s weighted average lease expiry (“WALE”) remained healthy at 4.4 years by net lettable area (“NLA”) and 3.4 years by gross rental income (“GRI”), underpinned by a well-spread lease expiry profile with only 4.8% of NLA and 7.7% by GRI due for renewal in FY2027.

Positive Retail Rental Reversion and Strong Tenant Sales Momentum

Lendlease REIT’s retail portfolio achieved a positive rental reversion of 10.0%¹ for 1Q FY2027. Visitation and tenant sales grew 27.4% and 45.5% YoY respectively, mainly driven by the inclusion of PLQ Mall for the full quarter. Excluding PLQ Mall, like-for-like visitation and tenant sales increased 6.7% and 8.1% YoY respectively.

During the quarter, Lendlease REIT continued to strengthen its retail offering by welcoming new-to-portfolio and new-to-market tenants, including Gentlewomen and LSOUL at 313@somerset, heytea and PastaGo at PLQ Mall and Setirom at Jem. These additions are expected to support footfall across the portfolio.

The reconfiguration of approximately 16,000 sq ft of space at PLQ Mall remains on track for completion by end-2026, with new tenants expected to enhance the mall’s positioning and support income growth.

Capital Management

Reduced Cost of Debt

As of 30 September 2026, gross borrowings stood at S$1,679.9 million, with gearing lowered to 38.7% from 38.9% as of 30 June 2026.

The weighted average cost of debt³ improved to 2.50% per annum, from 2.75% per annum reported for FY2026, attributed mainly to the loans associated with PLQ Mall that were refinanced at a lower cost of borrowing. As at 30 September 2026, approximately 68% of Lendlease REIT’s borrowings are hedged to fixed rates.  

The interest coverage ratio (“ICR”)⁴ remained healthy at 2.1 times⁵, with the benefits of the lower blended cost of funding from the June 2026 perpetual securities refinancing set to accrue progressively over time.

Mr. Guy Cawthra, Chief Executive Officer of the Manager, said, “Despite ongoing global uncertainty and macroeconomic headwinds, we are encouraged by our strong start to FY2027. Our portfolio has demonstrated resilience, underpinned by healthy leasing momentum and continued execution of our capital management initiatives. We look to build on this momentum in the quarters ahead, supported by the full-period contribution from PLQ Mall and the positive rental reversions secured over the past year.”

Award and Recognition

Global Sector Leader and Regional Sector Leader in the Retail category

In the GRESB 2026 Assessment, Lendlease REIT retained its title as Regional Sector Leader (Asia Retail Listed) for the seventh consecutive year, ranking first across all peer groups with a score of 96.6, well above the GRESB average of 80.9. Lendlease REIT was also recognised as the Global Sector Leader (Retail Listed), underscoring its sustainability leadership on a global scale.

Separately, Lendlease and Lendlease REIT received the Impact Enterprise Excellence Award (Large Enterprise) at the Sustainability Impact Awards 2026, in recognition of the strength of its sustainability strategy and its positive environmental and social impact.

About Lendlease Global Commercial REIT

Listed on 2 October 2019, Lendlease Global Commercial REIT (“Lendlease REIT”) is established with the principal investment strategy of investing, directly or indirectly, in a diversified portfolio of stabilised income-producing real estate assets located globally, which are used primarily for retail and/or office purposes.

As at 30 June 2026, its portfolio comprises leasehold properties in Singapore namely Jem (retail) (a suburban retail property), 313@somerset (a prime retail property), PLQ Mall (a suburban retail property) as well as freehold interest in three Grade A commercial buildings in Milan. These properties have a total value of approximately S$4.2 billion. Other investments include a stake in Parkway Parade (an office and retail property) and development of Grange House (a multifunctional event space) adjacent to 313@somerset.

Lendlease REIT is managed by Lendlease Global Commercial Trust Management Pte. Ltd., an indirect wholly-owned subsidiary of Lendlease Corporation Limited.

About the Sponsor – Lendlease Corporation Limited

Lendlease is an international real estate group listed on the Australian Securities Exchange. Their core capabilities are reflected in their operating segments of Investments, Development and Construction. Lendlease draws on this expertise to realise opportunities that create real value and returns for their partners and customers, as well as the communities who experience the places they shape. For more information, please visit: www.lendlease.com.

For more information on Lendlease REIT, please contact Investor Relations:

Lendlease Global Commercial Trust Management Pte. Ltd.
Ling Bee Lin
enquiry@lendleaseglobalcommercialreit.com
Tel: +65 6671 7374

Important Notice

This press release is for information purposes only and does not constitute or form part of an offer, invitation or solicitation of any offer to purchase or subscribe for any securities of Lendlease Global Commercial REIT (“Lendlease REIT”) in Singapore or any other jurisdiction nor should it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The value of units in Lendlease REIT (the “Units”) and the income derived from them may fall as well as rise. Units are not obligations of, deposits in, or guaranteed by Lendlease Global Commercial Trust Management Pte. Ltd. (the “Manager”), DBS Trustee Limited (as trustee of Lendlease REIT) or any of their affiliates.

This press release may contain forward-looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from similar developments, shifts in expected levels of property rental income, changes in operating expenses, (including employee wages, benefits and training costs), property expenses and governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business.

An investment in Units is subject to investment risks, including the possible loss of the principal amount invested. Holders of Units (“Unitholder”) have no right to request the Manager to redeem or purchase their Units while the Units are listed. It is intended that Unitholders may only deal in their Units through trading on Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing of the Units on SGX-ST does not guarantee a liquid market for the Units.

This press release is not to be distributed or circulated outside of Singapore. Any failure to comply with this restriction may constitute a violation of United State securities laws or the laws of any other jurisdiction.

The past performance of Lendlease REIT is not necessarily indicative of its future performance.

_______________________

_{¹ Year-to-date as at 30 September 2026, comparing the weighted average rent of outgoing and incoming leases.
² Lettable area for Milan assets is based on latest valuation report.
³ Excludes amortisation of debt-related transaction costs.
⁴ Calculation is in accordance with the Property Funds Appendix of the Code on Collective Investment Schemes (“PFA”). The ICR in accordance with loan agreements exceeds 4.0 times, in excess of debt covenant at 2.0 times.
⁵ Per the PFA, calculation is based on a trailing 12 months period ending on the date of the latest reported financial results. ICR as at both 30 September 2026 and 30 June 2026 is based on the last reported financial results as at 30 June 2026.}

Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)

Fully treated, randomized, double-blind n=90 Part A population sets up Annamycin dose selection for Part B, with balanced representation of AML patients who failed 7+3 chemotherapy and venetoclax-based regimens

HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML). The Company remains on track to report comprehensive Part A data in the first quarter of 2027.

Reaching this treatment milestone represents continued execution in the MIRACLE trial as the Company advances toward a comprehensive analysis of the full 90-patient Part A population. The planned Q1 2027 data readout is expected to provide important insights into the potential of AnnAraC across clinically distinct R/R AML patient populations and support selection of the optimal Annamycin dose for advancement into Part B of the trial.

The expanded Part A dataset is expected to provide further insight into AnnAraC in patients who have relapsed from or are refractory to different first-line AML treatment approaches, including intensive 7+3 chemotherapy and venetoclax-based regimens. The Company expects the final Part A population to reflect an approximately 50/50 split between these treatment groups, compared with an approximately 70/30 split, respectively, among the first 45 subjects. This broader representation is expected to help characterize AnnAraC’s potential across patient populations with differing treatment histories and clinical challenges.

“Reaching the completion of dosing in Part A represents another important step toward our planned Q1 2027 comprehensive n=90 data readout,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “Combined with the continued absence of cardiotoxicity in blinded interim data, we believe our Q1 2027 readout positions us to select our Part B dose and to define Annamycin’s potential role across today’s R/R AML landscape.”

About the MIRACLE Trial

MIRACLE is a pivotal Phase 2/3 study of Annamycin in combination with cytarabine for the treatment of adult subjects with AML who are refractory to, or have relapsed (R/R) after, induction therapy. Part A of the trial is a randomized, double-blind portion of the study that compares two different doses of Annamycin plus cytarabine to a control arm of cytarabine plus placebo, all with just one cycle of therapy.

Importantly, as specified by the MIRACLE protocol, remission rates for all three arms, including the control arm, reflect outcomes measured after only a single cycle of therapy. The most commonly cited historical benchmarks in this setting, including the MIRROS and CLASSIC I studies, as well as Moleculin’s own MB-106 study, permitted multiple cycles of treatment. The Company therefore expects absolute remission rates for both the control and Annamycin arms to be lower than those reported in such multi-cycle datasets and believes the most meaningful comparison is the performance of the Annamycin arms relative to the concurrent, randomized control arm evaluated on the same single-cycle basis.

The comprehensive Part A analysis is expected to evaluate efficacy and safety across the complete randomized population and support selection of the optimal Annamycin dose for advancement into Part B of MIRACLE.

For additional information on the MIRACLE trial, please visit ClinicalTrials.gov and reference Identifier NCT06788756.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the continued absence of cardiotoxicity based on blinded interim data, expected timing of the comprehensive Part A data readout in Q1 2027, the anticipated composition of the Part A population including the expected approximate 50/50 split between patients who failed intensive 7+3 chemotherapy and those who failed venetoclax-based regimens, the potential for Part A data to support dose selection for Part B, and the potential for Part A data to support dose selection for Part B. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today welcomed a significant development in the U.S. regulatory landscape for compounded peptides, which the Company believes is supportive of its strategic investment in Pep’d Inc., a U.S.-based peptide and telehealth company.

The U.S. Department of Health and Human Services (“HHS”) has announced an interim enforcement discretion policy covering six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 while the U.S. Food and Drug Administration (“FDA”) continues the rulemaking process concerning the Section 503A Bulks List.

Under the new policy, HHS has stated that it does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities or licensed physicians compounding products containing these specified peptides, provided the detailed conditions of the policy and other applicable requirements of Section 503A of the Federal Food, Drug, and Cosmetic Act are satisfied.

CDT believes the development represents an important evolution of the U.S. regulatory framework for peptides by establishing a more clearly defined pathway through which specified peptides may be compounded and prescribed to individual patients under appropriate medical supervision and quality controls.

The new HHS policy potentially expands the addressable opportunity available to compliant participants in the U.S. peptide market while increasing the importance of physician oversight, domestic pharmacy fulfillment, product quality, testing and regulatory compliance.

James Bligh, Chief Executive Officer of CDT Equity, commented:

“CDT invested in Pep’d because we believe peptides represent an important and rapidly developing area of healthcare, and this week’s announcement from HHS is an encouraging development for the sector. While the policy remains interim and the peptides covered by it have not been approved by the FDA, we believe this represents an important step in the evolution of the U.S. peptide market and a positive development for CDT’s investment in this hugely exciting sector.”

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors

CDT Equity Inc.
info@cdtequity.com

Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development 

Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes and Other Large Chronic-Disease Markets

SAN DIEGO, Oct. 30, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced receipt of an additional $1.5 million funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversible contraceptive based on Daré Bioscience’s intelligent drug delivery system (DARE-IDDS) platform.

With this installment, Daré Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The remaining approximately $5.6 million of the up to approximately $48.9 million commitment is tied to the future achievement of development and other milestones specified in the grant agreement. The funding will support continued preclinical development of DARE-LARC1, including nonclinical studies, activities intended to support an Investigational New Drug (IND) application, and other program-related work.

“Every installment we receive under this grant agreement reflects real progress on a program we believe has the potential to meaningfully expand contraceptive choice for women around the world,” said Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience. “Importantly, this funding does not dilute our shareholders while enabling us to keep advancing DARE-LARC1 toward an IND submission. It also validates development of the DARE-IDDS platform itself, and that validation is the foundation for the strategic discussions to potentially extend the application of this technology into obesity, diabetes and other chronic diseases.”

Extending the DARE-IDDS Platform Beyond Contraception

Daré Bioscience believes the DARE-IDDS platform may have potential beyond women’s health, including with GLP-1 analogs, anti-obesity medications, hormone therapies for areas such as diabetes, breast cancer, and infertility, and neurologic disease treatments such as for Parkinson’s disease, where long-term dosing and treatment burden are central challenges. Many current therapies in these areas rely on frequent injections or daily dosing, and maintaining adherence over months and years can be difficult for patients. A device designed to enable programming not only how much drug is released, but when, could offer an alternative approach. Daré Bioscience is exploring strategic collaborations with companies developing therapies in these areas to evaluate the DARE-IDDS platform in additional indications.

Advancing Long-Acting Contraception

DARE-LARC1 is being developed as a long-acting contraceptive that uses a programmable implantable device (DARE-IDDS) to deliver levonorgestrel over an extended period. By combining an active pharmaceutical ingredient found in several types of contraceptive products with a device designed to control the timing and duration of drug release, the DARE-LARC1 program aims to offer an alternative approach to contraception that would not require daily administration.

“The DARE-IDDS technology was engineered from the ground up for flexibility, to enable control over not just how much drug is released, but when. That design philosophy is what gives us confidence the platform may have utility in therapeutic areas beyond contraception, and we look forward to generating the data to show it,” commented Annie Thurman, MD, FACOG, Medical Director of Daré Bioscience.

Looking Ahead

Daré Bioscience expects to continue advancing DARE-LARC1 through nonclinical development and activities intended to support a future IND submission. Under the grant agreement, Daré Bioscience’s receipt of additional funding is contingent on achieving specified development milestones and other requirements. The Company is also exploring potential collaborations to evaluate the application of DARE-IDDS in additional therapeutic areas.

DARE-IDDS is an investigational device in preclinical development. It has not been approved or cleared for clinical investigation in humans or for any use in humans. The DARE-IDDS features described in this press release are based on the results of technological proof-of-concept studies.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build,” “explore,” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-LARC1’s potential as a safe and effective long-acting reversible contraceptive product; continued development of DARE-LARC1; future submission of an IND application for DARE-LARC1; use of the funding installment received and potential for Daré Bioscience to receive additional funding under the grant agreement relating to DARE-LARC1; the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering discrete doses over periods ranging from months to years and electronic dose programming; the potential application of DARE-IDDS in a broad range of therapeutic areas, including obesity, diabetes, breast cancer, infertility, and Parkinson’s disease; the potential of DARE-IDDS to improve treatment adherence and reduce treatment burden; and the potential for Daré Bioscience to enter into strategic collaborations for application of DARE-IDDS outside of contraception, including in large chronic disease markets.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: advancing DARE-LARC1 and any future product candidate utilizing DARE-IDDS through preclinical stage development and into human clinical trials; the ability of product candidates utilizing DARE-IDDS to demonstrate acceptable safety, tolerability and efficacy, including contraceptive effectiveness, in humans; the potential that product candidates utilizing DARE-IDDS may not demonstrate the dose capacity, duration of drug storage and delivery, or wireless connectivity and remote treatment monitoring and adjustment functionality anticipated based on technological proof-of-concept studies of DARE-IDDS; the risk that positive findings in technological proof-of-concept studies, other nonclinical studies and/or early clinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; delays, increased costs, or failure in completing necessary nonclinical and clinical studies of a product candidate, including due to unanticipated requirements for additional testing; potentially more complex, costly or lengthy development and approval requirements for drug-device combination product candidates; delays or failure to obtain U.S. Food and Drug Administration (FDA) or foreign regulatory approval for a product candidate; achieving anticipated treatment adherence or reduction in treatment burden benefits with any DARE-IDDS-based product, if approved; difficulties establishing and maintaining relationships with development and/or commercial collaborators; Daré Bioscience’s dependence on third parties to conduct nonclinical and clinical studies and manufacture and supply clinical trial material and commercial product, and the performance and resource commitments of such third parties; difficulties in manufacturing drug product candidates and their components at the required quality, stability and scale for clinical trials and commercialization; Daré Bioscience’s ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and a private foundation and the risk that such funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular stage of development as anticipated; Daré Bioscience’s ability to achieve the milestones and meet other requirements to receive additional funding under the grant agreement; potential suspension and delisting of Daré Bioscience’s common stock from The Nasdaq Capital Market; failure of any products, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; the risk that developments by competitors make Daré Bioscience’s products or product candidates less competitive or obsolete; Daré Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience’s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience’s products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience’s ability to raise additional capital or on Daré Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Daré Bioscience’s technology systems and/or significantly disrupt Daré Bioscience’s business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.

PHOENIX, Oct. 30, 2026 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share).

The dividend will be payable on November 30, 2026, to holders of record at the close of business on November 16, 2026.

About Global Water Resources

Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 systems which provide water, wastewater, and recycled water service. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix and Tucson. Global Water recycles over 1 billion gallons of water annually with 19.9 billion gallons recycled since 2004.

The company has been recognized for its highly effective implementation of Total Water Management (TWM). TWM is an integrated approach to managing the entire water cycle that involves owning and operating water, wastewater and recycled water utilities within the same geographic area in order to maximize the beneficial use of recycled water. It enables smart water management programs such as remote metering infrastructure and other advanced technologies, rate designs, and incentives that result in real conservation. TWM helps protect water supplies in water-scarce areas experiencing population growth.

Global Water has received numerous industry awards, including national recognition as a ‘Utility of the Future Today’ for its superior water reuse practices by a national consortium of water and conservation organizations led by the Water Environment Federation (WEF). The company also received Cityworks’ Excellence in Departmental Practice Award for demonstrating leadership and creativity in applying public asset management strategies to daily operations and long-term planning.

To learn more, visit www.gwresources.com.

Company Contact:	Investor Relations Contact:
Michael Liebman	Ron Both or Grant Stude
CFO and EVP	Encore Investor Relations
Tel (480) 999-5104	Tel (949) 432-7450
Email Contact	Email Contact

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Oral Presentation Details

Title: A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
Abstract Number: 1189
Presenter: Justin Moser, M.D., HonorHealth Research Institute
Presentation Time: Saturday, November 7, 2026; 2:30-2:45 p.m. MT
Location: North Building – 300 Level – Halls BC
Session 205: Clinical Oral Abstract Session 2, 1:30-3:00 p.m. MT
Session Schedule: https://www.sitcancer.org/2026/schedule/sitc-2026-schedule#session-1643

Details for the poster presentation is as follows:

Title: A Phase 1b/2 study of the tumor-activated IL-12 prodrug WTX-330 in patients with relapsed/refractory solid tumors
Abstract Number: 494
Session Date and Time: Saturday, November 7, 2026; 9 a.m.–8:30 p.m. MT
Location: North Building -Lower Level – Exhibition Halls 4-6

About Werewolf Therapeutics
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. Werewolf Therapeutics has designed conditionally activated INDUKINE™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf Therapeutics’ clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.

WEREWOLF^®, the WEREWOLF logo, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Company Contact:
Jonathan Owen
SVP, General Counsel and Secretary
Werewolf Therapeutics
jowen@werewolftx.com 

BROOMFIELD, Colo., Oct. 30, 2026 (GLOBE NEWSWIRE) — Gogo (NASDAQ: GOGO) today announced that it has appointed Amy Greene as Vice President of Investor Relations, Communications and Government Affairs.

A seasoned financial communications professional, Ms. Greene brings over 20 years of experience in the financial industry, with a proven track record of building and maintaining strong relationships with investors and across company stakeholders. Prior to joining Gogo, she served as Managing Partner of Eamon Capital Management, a boutique wealth management provider. She previously led investor relations and corporate engagement at Natura &Co, Avon Products, Inc. and GNC Holdings Inc., following a 10-year career publishing investment research on consumer products companies.

“We are pleased to have a communications professional of Amy’s caliber join the Gogo team,” said Chris Moore, CEO of Gogo. “She brings decades of experience in sell-side research and communications combined with a deep knowledge of capital markets and a strong network of relationships within the investment community. We look forward to the value she will add in engaging all of our stakeholders as Gogo continues its transformation into a global provider of high-speed broadband to the underpenetrated business and military/government aviation markets.”

“I am thrilled to join Gogo at such an exciting time in the Company’s history,” said Ms. Greene. “Gogo’s stakeholders are beginning to recognize the unique value proposition the Company brings to the marketplace and its compelling investment thesis, and I look forward to engaging with them as Gogo continues its transformation.”

About Gogo

Gogo is the only multi-orbit, multi-band in-flight connectivity provider offering connectivity technology purpose-built for business and military/government aviation. Its industry-leading product portfolio offers best-in-class solutions for all aircraft types, from small to large and heavy jets and beyond.

The Gogo offering uniquely incorporates air-to-ground systems with access to high-speed satellite networks, which aim to deliver consistent, global tip-to-tail connectivity through a sophisticated suite of software, hardware, and advanced infrastructure supported by a 24/7/365 in-person customer support team.

Gogo consistently strives to set new standards for reliability, security, and innovation and is shaping the future of inflight aviation to make it easier for every customer to stay connected beyond all expectations.

Media Relations Contact	Investor Relations Contact
Stacey Giglio	Amy Greene
sgiglio@gogoair.com	agreene@gogoair.com
+1 321 361 6101	+1 303 301 3313

Company Highlights:

• GAAP net loss of $(85.4) million, or $(0.51) per diluted common share
• Distributable loss¹ of $(0.04) per diluted common share, or distributable earnings of $0.08 excluding $21.7 million of net realized losses from the resolution of certain legacy assets
• Suspends quarterly cash dividend on common stock during this challenging environment to preserve capital and maintain financial flexibility
• Closed an $825.0 million collateralized securitization vehicle with enhanced leverage, generating ~$50 million of additional liquidity
• Servicing portfolio of ~$36.80 billion, agency loan originations of $907.0 million
• Structured loan portfolio of ~$12.00 billion, originations of $459.2 million and runoff of $574.0 million

UNIONDALE, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced financial results for the third quarter ended September 30, 2026. Arbor reported a net loss for the quarter of $(85.4) million, or $(0.51) per diluted common share, compared to net income of $38.5 million, or $0.20 per diluted common share for the quarter ended September 30, 2025. Distributable loss for the quarter was $(6.9) million, or $(0.04) per diluted common share, compared to distributable earnings of $72.9 million, or $0.35 per diluted common share for the quarter ended September 30, 2025.

Agency Business

Loan Origination Platform

	Agency Loan Volume ($ in thousands)
	Quarter Ended
	September 30, 2026			June 30, 2026
Fannie Mae	$	574,805		$	619,130
Freddie Mac		185,679			428,278
FHA		129,456			8,083
SFR-Fixed Rate		17,039			21,272
Total Originations	$	906,979		$	1,076,763
Total Loan Sales	$	978,152		$	1,143,438
Total Loan Commitments	$	819,243		$	1,211,900

For the quarter ended September 30, 2026, the Agency Business generated revenues of $57.5 million, compared to $64.5 million for the second quarter of 2026. Gain on sales, including fee-based services, net was $10.9 million for the quarter, reflecting a margin of 1.12%, compared to $15.2 million and 1.33% for the second quarter of 2026. Income from mortgage servicing rights was $11.1 million for the quarter, reflecting a rate of 1.35% as a percentage of loan commitments, compared to $12.1 million and 1.00% for the second quarter of 2026.

At September 30, 2026, loans held-for-sale was $236.8 million, with financing associated with these loans totaling $222.8 million.

Fee-Based Servicing Portfolio

The Company’s fee-based servicing portfolio totaled $36.80 billion at September 30, 2026. Servicing revenue, net was $25.7 million for the quarter and consisted of servicing revenue of $44.1 million, net of amortization of mortgage servicing rights totaling $18.4 million.

	Fee-Based Servicing Portfolio ($ in thousands)
	September 30, 2026							June 30, 2026
	UPB			Wtd. Avg. Fee (bps)		Wtd. Avg. Life (years)		UPB			Wtd. Avg. Fee (bps)		Wtd. Avg. Life (years)
Fannie Mae	$	24,545,520		43.6		5.0		$	24,419,734		43.9		5.2
Freddie Mac		7,664,059		17.4		5.5			7,672,121		17.6		5.7
Private Label		2,461,505		18.7		3.8			2,477,077		18.7		4.1
FHA		1,641,273		13.8		18.9			1,585,871		13.8		18.9
SFR-Fixed Rate		255,087		20.0		3.9			272,226		20.0		3.8
Bridge		235,888		10.0		1.7			277,333		10.4		1.7
Total	$	36,803,332		34.7		5.6		$	36,704,362		35.0		5.8

Loans sold under the Fannie Mae program contain an obligation to partially guarantee the performance of the loan (“loss-sharing obligations”) and includes $36.9 million for the fair value of the guarantee obligation undertaken at September 30, 2026. The Company recorded a $12.4 million net provision for loss sharing associated with CECL for the third quarter of 2026. At September 30, 2026, the Company’s total CECL allowance for loss-sharing obligations was $87.3 million, representing 0.36% of the Fannie Mae servicing portfolio.

Structured Business

Portfolio and Investment Activity

	Structured Portfolio Activity ($ in thousands)
	Quarter Ended
	September 30, 2026						June 30, 2026
	UPB			%			UPB			%
Bridge:
SFR	$	367,114		80	%		$	490,617		71	%
Multifamily		14,000		3	%			159,550		23	%
		381,114		83	%			650,167		94	%
Construction – Multifamily		43,318		9	%			38,810		6	%
Mezzanine/Preferred Equity		34,793		8	%			—		—	%
Total Originations	$	459,225		100	%		$	688,977		100	%
Number of Loans Originated		12						14
Commitments:
SFR	$	91,912					$	48,785
Construction – Multifamily		104,500						—
Total Commitments	$	196,412					$	48,785
Loan Runoff	$	573,989					$	539,745

	Structured Portfolio ($ in thousands)
	September 30, 2026						June 30, 2026
	UPB			%			UPB			%
Bridge:
Multifamily	$	7,682,346		64	%		$	7,895,187		65	%
SFR		3,463,471		29	%			3,376,845		28	%
Other		46,519		<1%				46,519		<1%
		11,192,336		94	%			11,318,551		94	%
Mezzanine/Preferred Equity		527,888		4	%			502,998		4	%
Construction – Multifamily		279,494		2	%			285,482		2	%
Total Portfolio	$	11,999,718		100	%		$	12,107,031		100	%

At September 30, 2026, the loan and investment portfolio’s unpaid principal balance (“UPB”), excluding loan loss reserves, was $12.00 billion, with a weighted average interest rate of 6.54%, compared to $12.11 billion and 6.50% at June 30, 2026. Including certain fees earned and costs associated with the loan and investment portfolio, the weighted average interest rate was 6.97% at September 30, 2026, compared to 6.95% at June 30, 2026.

The average balance of the Company’s loan and investment portfolio during the third quarter of 2026, excluding loan loss reserves, was $12.11 billion with a weighted average yield of 6.84%, compared to $12.08 billion and 7.21% for the second quarter of 2026. The decrease in the weighted average yield was primarily due to additional delinquencies and rate modifications in the third quarter of 2026.

During the third quarter of 2026, the Company recorded a $53.0 million net provision for loan losses associated with CECL. At September 30, 2026, the Company’s total allowance for loan losses was $210.1 million. The Company had thirty-two non-performing loans with a UPB of $647.6 million, before related loan loss reserves of $41.9 million, compared to nineteen non-performing loans with a UPB of $428.8 million, before loan loss reserves of $31.1 million at June 30, 2026. In addition, the Company recorded $34.1 million of impairments on six real estate owned properties.

In addition, at September 30, 2026, the Company had two non-accrual loans with a UPB of $95.9 million that were less than 60 days past due, compared to three non-accrual loans with a UPB of $94.9 million at June 30, 2026.

During the third quarter of 2026, the Company modified 6 loans to borrowers experiencing financial difficulty with a total UPB of $192.1 million, the majority of which had borrowers investing additional capital to recapitalize their deals.

The Company foreclosed on one loan with a UPB of $13.2 million and sold five existing REO properties for $39.0 million.

Financing Activity

The balance of debt that finances the Company’s loan and investment portfolio at September 30, 2026 was $10.75 billion with a weighted average interest rate including fees of 6.69%, as compared to $10.48 billion and a rate of 6.38% at June 30, 2026.

The average balance of debt that finances the Company’s loan and investment portfolio for the third quarter of 2026 was $10.70 billion, as compared to $10.51 billion for the second quarter of 2026. The average cost of borrowings for the third quarter of 2026 was 6.66%, compared to 6.56% for the second quarter of 2026. The increase in average cost was primarily due to the convertible senior unsecured notes offering, as well as an increase in the average SOFR rate in the third quarter of 2026.

The Company completed an $825.0 million collateralized securitization secured initially by a portfolio of real estate related assets and cash. Investment grade-rated notes totaling $730.1 million were issued, and the Company retained subordinate interests in the issuing vehicle of $112.4 million, including $17.5 million of the investment grade notes. The facility has a two and a half year asset replenishment period and an initial weighted average interest rate of the notes issued to third parties of 1.70% plus term SOFR, excluding fees and transaction costs.

The Company completed an upsized $375.0 million offering of 6.25% convertible senior notes due 2029. The Company used the offering proceeds to redeem its $270.0 million of 4.50% senior notes and to repurchase common stock through two separate transactions: $11.6 million to repurchase ~2.1 million shares concurrently with the offering and $114.3 million to repurchase ~18.9 million shares pursuant to a prepaid forward stock repurchase transaction.

Dividend

The Company announced today that its Board of Directors has elected to suspend its quarterly common stock dividend, effective immediately. The decision reflects the Company’s continued focus on preserving capital and maintaining financial flexibility to address upcoming debt maturities and support the resolution of legacy assets. The Company will continue to evaluate its dividend policy based upon market conditions and the Company’s performance, capital needs, and REIT distribution requirements with a continued focus on preserving book value and maximizing long-term shareholder value.

Earnings Conference Call

The Company will host a conference call today at 10:00 a.m. Eastern Time. A live webcast and replay of the conference call will be available at www.arbor.com in the investor relations section of the Company’s website, or you can access the call telephonically at least ten minutes prior to the conference call. The dial-in numbers are (833) 419-0865 for domestic callers and (785) 838-9333 for international callers. Please use participant passcode ABRQ326 when prompted by the operator.

A telephonic replay of the call will be available until November 6, 2026. The replay dial-in numbers are (800) 839-2435 for domestic callers and (402) 220-7212 for international callers.

About Arbor Realty Trust, Inc.

Arbor Realty Trust, Inc. (NYSE: ABR) is a nationwide real estate investment trust and direct lender, providing loan origination and servicing for multifamily, single-family rental (SFR) portfolios, and other diverse commercial real estate assets. Headquartered in New York, Arbor manages a multibillion-dollar servicing portfolio, specializing in government-sponsored enterprise products. Arbor is a leading Fannie Mae DUS® lender, Freddie Mac Optigo® Seller/Servicer, and an approved FHA Multifamily Accelerated Processing (MAP) lender. Arbor’s product platform also includes bridge, CMBS, mezzanine, and preferred equity loans. Rated by Standard and Poor’s and Fitch Ratings, Arbor is committed to building on its reputation for service, quality, and customized solutions with an unparalleled dedication to providing our clients excellence over the entire life of a loan.

Safe Harbor Statement

Certain items in this press release may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Arbor can give no assurance that its expectations will be attained. Factors that could cause actual results to differ materially from Arbor’s expectations include, but are not limited to, changes in economic conditions generally, and the real estate markets specifically, continued ability to source new investments, changes in interest rates and/or credit spreads, and other risks detailed in Arbor’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other reports filed with the SEC. Such forward-looking statements speak only as of the date of this press release. Arbor expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Arbor’s expectations with regard thereto or change in events, conditions, or circumstances on which any such statement is based.

Notes

1. During the quarterly earnings conference call, the Company may discuss non-GAAP financial measures as defined by SEC Regulation G. In addition, the Company has used non-GAAP financial measures in this press release. A supplemental schedule of non-GAAP financial measures and the comparable GAAP financial measure can be found on the last two pages of this release.

Contact:	Arbor Realty Trust, Inc. Investor Relations 516-506-4200 InvestorRelations@arbor.com

ARBOR REALTY TRUST, INC. AND SUBSIDIARIES Consolidated Statements of Operations – (Unaudited) ($ in thousands—except share and per share data)
	Quarter Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Interest income	$	221,921			$	223,001			$	687,826			$	703,997
Interest expense		184,249				184,735				537,212				521,564
Net interest income		37,672				38,266				150,614				182,433
Other revenue:
Gain on sales, including fee-based services, net		10,925				23,340				38,607				49,779
Mortgage servicing rights		11,078				15,538				32,849				34,598
Servicing revenue, net		25,741				29,652				75,360				82,692
Property operating income		7,873				4,189				24,246				14,028
Gain (loss) on derivative instruments, net		279				(2,206	)			827				1,413
Other income, net		525				3,650				4,858				12,059
Total other revenue		56,421				74,163				176,747				194,569
Other expenses:
Employee compensation and benefits		42,524				44,169				135,304				131,386
Selling and administrative		15,384				13,698				48,205				44,868
Property operating expenses		11,804				7,296				36,438				17,572
Depreciation and amortization		5,868				5,355				18,901				14,947
Impairment loss on real estate owned		34,050				—				60,200				—
Provision for loss sharing, net		12,625				8,256				30,634				14,258
Provision for credit losses, net		55,506				19,694				99,485				47,773
Total other expenses		177,761				98,468				429,167				270,804
(Loss) income before extinguishment of debt, gain (loss) on real estate, (loss) income from equity affiliates and income taxes		(83,668	)			13,961				(101,806	)			106,198
Loss on extinguishment of debt		—				—				—				(2,319	)
Gain (loss) on real estate		1,574				(555	)			(498	)			(4,813	)
(Loss) income from equity affiliates		(1,494	)			46,204				4,810				47,224
Benefit from (provision for) income taxes		1,181				(7,594	)			(4,054	)			(14,583	)
Net (loss) income		(82,407	)			52,016				(101,548	)			131,707
Preferred stock dividends		10,342				10,342				31,027				31,027
Net (loss) income attributable to noncontrolling interest		(7,395	)			3,211				(10,507	)			7,828
Net (loss) income attributable to common stockholders	$	(85,354	)		$	38,463			$	(122,068	)		$	92,852
Basic (loss) earnings per common share	$	(0.51	)		$	0.20			$	(0.66	)		$	0.48
Diluted (loss) earnings per common share	$	(0.51	)		$	0.20			$	(0.66	)		$	0.48
Weighted average shares outstanding:
Basic		168,916,898				193,748,462				184,546,941				192,028,656
Diluted		168,916,898				210,517,762				184,546,941				208,807,751
Dividends declared per common share	$	0.17			$	0.30			$	0.64			$	1.03

ARBOR REALTY TRUST, INC. AND SUBSIDIARIES Consolidated Balance Sheets ($ in thousands—except share and per share data)
	September 30, 2026
	(Unaudited)				December 31, 2025
Assets:
Cash and cash equivalents	$	439,689			$	482,875
Restricted cash		250,877				67,347
Loans and investments, net (allowance for credit losses of $210,104 and $145,971)		11,764,328				11,934,248
Loans held-for-sale, net		236,824				409,081
Capitalized mortgage servicing rights, net		315,014				340,842
Securities held-to-maturity, net (allowance for credit losses of $15,834 and $17,013)		156,211				156,087
Investments in equity affiliates		72,060				57,966
Real estate owned, net		491,170				498,938
Goodwill and other intangible assets		85,678				86,553
Other assets		425,157				460,966
Total assets	$	14,237,008			$	14,494,903
Liabilities and Equity:
Credit and repurchase facilities	$	5,176,866			$	5,149,651
Securitized debt		3,630,292				3,468,258
Senior unsecured notes		1,589,460				2,029,078
Convertible senior unsecured notes		365,478				—
Junior subordinated notes to subsidiary trust issuing preferred securities		146,112				145,497
Notes payable – real estate owned		254,977				222,965
Due to borrowers		26,328				33,451
Allowance for loss-sharing obligations		124,145				97,579
Other liabilities		281,757				281,271
Total liabilities		11,595,415				11,427,750
Equity:
Arbor Realty Trust, Inc. stockholders’ equity:
Preferred stock, cumulative, redeemable, $0.01 par value: 100,000,000 shares authorized, shares issued and outstanding by period:		633,683				633,683
Special voting preferred shares – 16,165,771 and 16,169,858 shares
6.375% Series D – 9,200,000 shares
6.25% Series E – 5,750,000 shares
6.25% Series F – 11,342,000 shares
Common stock, $0.01 par value: 500,000,000 shares authorized – 186,436,159 and 195,491,855 shares issued and outstanding		1,864				1,955
Additional paid-in capital		2,297,464				2,454,312
Accumulated deficit		(384,340	)			(136,597	)
Total Arbor Realty Trust, Inc. stockholders’ equity		2,548,671				2,953,353
Noncontrolling interest		92,922				113,800
Total equity		2,641,593				3,067,153
Total liabilities and equity	$	14,237,008			$	14,494,903

ARBOR REALTY TRUST, INC. AND SUBSIDIARIES Statement of Operations Segment Information – (Unaudited) ($ in thousands)
	Quarter Ended September 30, 2026
	Structured Business				Agency Business				Other (1)				Consolidated
Interest income	$	210,708			$	11,213			$	—			$	221,921
Interest expense		179,718				4,531				—				184,249
Net interest income		30,990				6,682				—				37,672
Other revenue:
Gain on sales, including fee-based services, net		—				10,925				—				10,925
Mortgage servicing rights		—				11,078				—				11,078
Servicing revenue		—				44,133				—				44,133
Amortization of MSRs		—				(18,392	)			—				(18,392	)
Property operating income		7,873				—				—				7,873
Gain on derivative instruments, net		—				279				—				279
Other income (loss), net		2,274				(1,749	)			—				525
Total other revenue		10,147				46,274				—				56,421
Other expenses:
Employee compensation and benefits		18,637				23,887				—				42,524
Selling and administrative		8,260				7,124				—				15,384
Property operating expenses		11,804				—				—				11,804
Depreciation and amortization		5,776				92				—				5,868
Impairment loss on real estate owned		34,050				—				—				34,050
Provision for loss sharing, net		—				12,625				—				12,625
Provision for credit losses, net		52,982				2,524				—				55,506
Total other expenses		131,509				46,252				—				177,761
(Loss) income before gain on real estate, loss from equity affiliates and income taxes		(90,372	)			6,704				—				(83,668	)
Gain on real estate		1,574				—				—				1,574
Loss from equity affiliates		(1,494	)			—				—				(1,494	)
Benefit from income taxes		390				791				—				1,181
Net (loss) income		(89,902	)			7,495				—				(82,407	)
Preferred stock dividends		10,342				—				—				10,342
Net loss attributable to noncontrolling interest		—				—				(7,395	)			(7,395	)
Net (loss) income attributable to common stockholders	$	(100,244	)		$	7,495			$	7,395			$	(85,354	)

(1)	Includes income (loss) allocated to the noncontrolling interest holders not allocated to the two reportable segments.

ARBOR REALTY TRUST, INC. AND SUBSIDIARIES Balance Sheet Segment Information – (Unaudited) ($ in thousands)
	September 30, 2026
	Structured Business			Agency Business			Consolidated
Assets:
Cash and cash equivalents	$	117,113		$	322,576		$	439,689
Restricted cash		213,041			37,836			250,877
Loans and investments, net		11,764,328			—			11,764,328
Loans held-for-sale, net		—			236,824			236,824
Capitalized mortgage servicing rights, net		—			315,014			315,014
Securities held-to-maturity, net		—			156,211			156,211
Investments in equity affiliates		72,060			—			72,060
Real estate owned, net		491,170			—			491,170
Goodwill and other intangible assets		12,500			73,178			85,678
Other assets		323,247			101,910			425,157
Total assets	$	12,993,459		$	1,243,549		$	14,237,008
Liabilities:
Debt obligations	$	10,940,366		$	222,819		$	11,163,185
Allowance for loss-sharing obligations		—			124,145			124,145
Other liabilities		218,399			89,686			308,085
Total liabilities	$	11,158,765		$	436,650		$	11,595,415

ARBOR REALTY TRUST, INC. AND SUBSIDIARIES Reconciliation of Distributable (Loss) Earnings to GAAP Net (Loss) Income – (Unaudited) ($ in thousands—except share and per share data)
	Quarter Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net (loss) income attributable to common stockholders	$	(85,354	)		$	38,463			$	(122,068	)		$	92,852
Adjustments:
Net (loss) income attributable to noncontrolling interest		(7,395	)			3,211				(10,507	)			7,828
Income from mortgage servicing rights		(11,078	)			(15,538	)			(32,849	)			(34,598	)
Deferred tax benefit		(2,179	)			(1,791	)			(6,970	)			(3,532	)
Amortization and write-offs of MSRs		20,082				18,906				60,515				59,595
Depreciation and amortization		6,813				6,089				21,503				17,240
Loss on extinguishment of debt		—				—				—				2,319
Provision for credit losses, net		46,783				18,381				66,437				27,572
Loss (gain) on derivative instruments, net		1,943				2,110				2,763				(3,261	)
Loss on real estate		20,392				369				38,310				5,035
Stock-based compensation		3,111				2,738				12,140				11,284
Distributable (loss) earnings (1)	$	(6,882	)		$	72,938			$	29,274			$	182,334
Diluted weighted average shares outstanding (1)		185,084,602				210,517,762				201,632,871				208,807,751
Diluted distributable (loss) earnings per share (1)	$	(0.04	)		$	0.35			$	0.15			$	0.87

(1)	Amounts are attributable to common stockholders and OP Unit holders. The OP Units are redeemable for cash, or at the Company’s option for shares of the Company’s common stock on a one-for-one basis.

The Company is presenting distributable earnings because management believes it is an important supplemental measure of the Company’s operating performance and is useful to investors, analysts and other parties in the evaluation of REITs and their ability to provide dividends to stockholders. Dividends are one of the principal reasons investors invest in REITs. To maintain REIT status, REITs are required to distribute at least 90% of their REIT-taxable income. The Company considers distributable earnings in determining its quarterly dividend and believes that, over time, distributable earnings is a useful indicator of the Company’s dividends per share.

The Company defines distributable earnings as net income (loss) attributable to common stockholders computed in accordance with GAAP, adjusted for accounting items such as depreciation and amortization (adjusted for unconsolidated joint ventures), non-cash stock-based compensation expense, income from MSRs, amortization and write-offs of MSRs, gains/losses on derivative instruments primarily associated with Private Label loans not yet sold and securitized, changes in fair value of GSE-related derivatives that temporarily flow through earnings, deferred tax provision (benefit), CECL provisions for credit losses (adjusted for realized losses as described below), gains/losses on the receipt of real estate from the settlement of loans and subsequent impairment losses on real estate owned prior to the sale of the real estate. The Company also adds back one-time charges such as acquisition costs and one-time gains/losses on the early extinguishment of debt and redemption of preferred stock.

The Company reduces distributable earnings for realized losses in the period management determines that a loan is deemed nonrecoverable in whole or in part. Loans are deemed nonrecoverable upon the earlier of: (1) when the loan receivable is repaid, or in the case of foreclosure, when the underlying asset is sold at which time any impairments and/or cumulative depreciation expense are realized; or (2) when management determines that it is nearly certain that all amounts due will not be collected. The realized loss amount is equal to the difference between the cash received, or expected to be received, and the book value of the asset.

Distributable earnings is not intended to be an indication of the Company’s cash flows from operating activities (determined in accordance with GAAP) or a measure of its liquidity, nor is it entirely indicative of funding the Company’s cash needs, including its ability to make cash distributions. The Company’s calculation of distributable earnings may be different from the calculations used by other companies and, therefore, comparability may be limited.

PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, taking place October 31-November 4 in Washington, D.C. At this year’s meeting, Integra will showcase its comprehensive neurosurgery portfolio through interactive educational experiences, hands-on training and technologies that support neurosurgeons across the continuum of care.

Conference attendees are invited to visit Integra at Booth 341 and participate in the CNS Skills Showdown, an interactive, educational experience that allows surgeons to test and refine procedural skills while learning about innovative neurosurgical technologies.

In addition, Integra will host a mobile hands-on laboratory on-site on Tuesday, November 3, providing attendees with practical product training opportunities across key areas of neurosurgical care, including:

• Aurora® Surgiscope® System
• DuraGen®Dural Graft Matrices, Durepair® Dura Regeneration Matrix and dural repair solutions
• CUSA® Clarity Ultrasonic Surgical Aspirator System
• Neurocritical care technologies and intracranial pressure (ICP) monitoring solutions

“As a practicing neurosurgeon, I’ve seen how hands-on experience and peer collaboration help turn innovation into meaningful advances in patient care,” said Ray Turner, M.D., corporate vice president and chief medical officer, Integra LifeSciences. “Some of the most important conversations in our field happen when surgeons share what they’re seeing in practice, challenge conventional thinking and learn from each other’s experiences. Integra technologies have long been part of my go-to toolkit, and I’m proud to stand behind products I also rely on in my own practice.”

An estimated 13.8 million patients worldwide require neurosurgical intervention each year, underscoring the importance of continued innovation, education, and collaboration across the specialty.¹ Integra’s neurosurgery portfolio includes technologies spanning neurocritical care, cerebrospinal fluid management, dural repair, visualization and tissue resection. The portfolio brings together established technologies such as the CUSA Clarity, celebrating 20 years within Integra’s neurosurgery portfolio, alongside newer innovations such as Aurora® Surgiscope® System.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

¹ Dewan MC, Rattani A, Fieggen G, et al. Global neurosurgery: the current capacity and deficit in the provision of essential neurosurgical care. Executive Summary of the Global Neurosurgery Initiative at the Program in Global Surgery and Social Change. Journal of Neurosurgery. 2018;130(4):1055-1064. doi:10.3171/2017.11.JNS171500.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f5acb50e-642f-413f-b559-d31a2a5e52d6

HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced the redemption of all $236 million aggregate principal amount outstanding of its 8.625% Senior Notes due 2030 (the “2030 Notes”). The notes are being redeemed at 100% of their principal amount, plus accrued and unpaid interest, using cash on hand.

The redemption further optimizes Weatherford’s capital structure, reduces Weatherford’s gross debt by $236 million, and is expected to reduce annualized cash interest expense by approximately $20 million. Following the redemption, none of Weatherford’s current outstanding debt is scheduled to mature for approximately the next seven years, providing significant financial flexibility to support the Company’s strategic priorities.

Anuj Dhruv, Weatherford’s Executive Vice President and Chief Financial Officer, commented, “This redemption is another step in strengthening our financial foundation and reflects the disciplined approach we continue to take toward capital allocation. Retiring higher-cost debt lowers our interest expense, extends our maturity runway, and gives us greater flexibility to invest in the opportunities that create the most value for Weatherford and our shareholders.”

About Weatherford

Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.

Forward-Looking Statement

This news release contains projections and forward-looking statements concerning expectations regarding future financial results. Such statements are only estimates based upon the current beliefs of Weatherford’s management and are subject to significant risks, assumptions, and uncertainties. Should one or more of these risks or uncertainties materialize, or underlying assumptions prove incorrect, actual results may vary materially from those indicated in our forward-looking statements. These risks and uncertainties are more fully described in Weatherford’s reports and registration statements filed with the Securities and Exchange Commission, including the risk factors described in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on any of the Company’s forward-looking statements. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

For Investors:
Luke Lemoine
Senior Vice President, Corporate Development & Investor Relations
+1 713-836-7777
investor.relations@weatherford.com

For Media:
Kelley Hughes
Vice President, Communications, Marketing & Sustainability
media@weatherford.com